Antibody–drug conjugates (ADCs) hold great promise for targeted cancer therapy, but their clinical success is often limited by hematotoxicity. Traditional models fail to predict these toxic effects with sufficient accuracy, particularly in the human bone marrow. In this post, we explore how Vivia Biotech’s proprietary ex vivo assay provides a translational solution to this challenge. By enabling simultaneous measurement of ADC efficacy and hematopoietic toxicity in a native microenvironment, this platform offers drug developers a powerful tool to optimize the therapeutic index, compare ADC candidates, and anticipate safety liabilities—early and reliably.

Despite advances in multiple myeloma therapy, predicting patient response remains a major challenge. Vivia Biotech addresses this gap with functional ex vivo profiling in whole bone marrow, revealing drug efficacy and resistance in real time. Learn how this approach enhances precision medicine in a complex treatment landscape.

Leading pharma and biotech companies rely on Vivia Biotech to generate human-relevant functional data early in the drug development process. Using patient-derived samples under native conditions, our ex vivo assays preserve the immune and stromal complexity of the tumor microenvironment—enabling precise evaluation of drug mechanisms, immune responses, and resistance pathways. With more than 190 projects completed, we provide mechanistic clarity and translational insight to accelerate oncology, hematology, and autoimmune disease pipelines.

The FDA’s regulatory shift away from animal testing has opened new avenues for preclinical innovation. Functional assays using native patient samples now offer a clinically translatable, ethical alternative for early drug evaluation. Learn how this paradigm is being implemented at Vivia Biotech to bridge discovery and clinical development.

In the preclinical phase of drug development, assessing how a compound affects diseased cells is fundamental. Traditionally, this has relied on functional assays that measure outcomes such as viability, proliferation, or cell death. These readouts provide a first indication of drug efficacy, particularly in systems that attempt to reproduce the biological context of the disease.